Veracyte (VCYT) Revenue & Revenue Breakdown
Veracyte Revenue Highlights
Latest Revenue (Y)
$361.05M
Latest Revenue (Q)
$96.84M
Main Segment (Y)
Testing
Main Geography (Y)
UNITED STATES
Veracyte Revenue by Period
Veracyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $361.05M | 21.76% |
| 2022-12-31 | $296.54M | 35.09% |
| 2021-12-31 | $219.51M | 86.85% |
| 2020-12-31 | $117.48M | -2.40% |
| 2019-12-31 | $120.37M | 30.82% |
| 2018-12-31 | $92.01M | 27.87% |
| 2017-12-31 | $71.95M | 10.55% |
| 2016-12-31 | $65.08M | 31.48% |
| 2015-12-31 | $49.50M | 29.62% |
| 2014-12-31 | $38.19M | 74.51% |
| 2013-12-31 | $21.88M | 88.20% |
| 2012-12-31 | $11.63M | 339.62% |
| 2011-12-31 | $2.65M | - |
Veracyte generated $361.05M in revenue during NA 2023, up 21.76% compared to the previous quarter, and up 392.41% compared to the same period a year ago.
Veracyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $96.84M | -1.38% |
| 2023-12-31 | $98.20M | 8.98% |
| 2023-09-30 | $90.11M | -0.24% |
| 2023-06-30 | $90.32M | 9.58% |
| 2023-03-31 | $82.42M | 2.65% |
| 2022-12-31 | $80.30M | 6.22% |
| 2022-09-30 | $75.59M | 3.74% |
| 2022-06-30 | $72.86M | 7.50% |
| 2022-03-31 | $67.78M | 0.66% |
| 2021-12-31 | $67.34M | 11.54% |
| 2021-09-30 | $60.37M | 9.55% |
| 2021-06-30 | $55.10M | 50.14% |
| 2021-03-31 | $36.70M | 6.27% |
| 2020-12-31 | $34.54M | 10.97% |
| 2020-09-30 | $31.12M | 50.31% |
| 2020-06-30 | $20.70M | -33.47% |
| 2020-03-31 | $31.12M | 4.68% |
| 2019-12-31 | $29.73M | -4.01% |
| 2019-09-30 | $30.97M | 2.78% |
| 2019-06-30 | $30.14M | 2.06% |
| 2019-03-31 | $29.53M | 14.68% |
| 2018-12-31 | $25.75M | 9.73% |
| 2018-09-30 | $23.47M | 3.14% |
| 2018-06-30 | $22.75M | 13.52% |
| 2018-03-31 | $20.04M | 2.27% |
| 2017-12-31 | $19.60M | 11.86% |
| 2017-09-30 | $17.52M | -4.82% |
| 2017-06-30 | $18.41M | 12.01% |
| 2017-03-31 | $16.43M | -10.00% |
| 2016-12-31 | $18.26M | -1.86% |
| 2016-09-30 | $18.60M | 26.77% |
| 2016-06-30 | $14.68M | 8.30% |
| 2016-03-31 | $13.55M | 9.85% |
| 2015-09-30 | $12.34M | 3.59% |
| 2015-06-30 | $11.91M | 6.15% |
| 2015-03-31 | $11.22M | -8.04% |
| 2014-12-31 | $12.20M | 24.00% |
| 2014-09-30 | $9.84M | 13.38% |
| 2014-06-30 | $8.68M | 16.06% |
| 2014-03-31 | $7.48M | 9.33% |
| 2013-12-31 | $6.84M | 22.24% |
| 2013-09-30 | $5.59M | 10.38% |
| 2013-06-30 | $5.07M | 15.60% |
| 2013-03-31 | $4.38M | -1.64% |
| 2012-12-31 | $4.46M | 38.24% |
| 2012-09-30 | $3.22M | - |
Veracyte generated $96.84M in revenue during Q4 2023, up -1.38% compared to the previous quarter, and up 120.61% compared to the same period a year ago.
Veracyte Revenue Breakdown
Veracyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Biopharmaceutical And Other | $33.36M | $19.87M | - | - | - |
| Testing | $250.54M | $58.86M | $101.97M | $107.36M | - |
| Product | $12.63M | $9.85M | $923.00K | - | - |
| Collaboration | - | - | - | $4.00M | - |
| Biopharmaceutical | - | - | $5.67M | $8.09M | - |
| Provision of Data | - | - | - | $7.00M | - |
| Service | - | - | - | $250.00K | $250.00K |
| Fulfillment of Obligations | - | - | - | $4.00M | - |
Veracyte's latest annual revenue breakdown by segment (product or service), as of Dec 22: Testing (84.49%), Biopharmaceutical And Other (11.25%), and Product (4.26%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing | $90.30M | $326.54M | $81.75M | $72.40M | $70.27M | $64.58M | $59.72M | $16.37M | $16.07M | $31.50M | $26.99M | - | - | - | - | - | - | - | - | - |
| Biopharmaceutical And Other | $3.00M | $18.92M | $4.56M | $6.13M | $6.80M | $7.70M | $10.04M | $8.82M | $11.16M | $6.51M | - | - | - | - | - | - | - | - | - | - |
| Product | $3.54M | $15.59M | $4.01M | $3.89M | $3.23M | $3.31M | $3.11M | $2.98M | $2.96M | $2.69M | $3.06M | $2.70M | $2.03M | $1.71M | $3.41M | $90.00K | $90.00K | $90.00K | - | - |
| Biopharmaceutical | - | - | - | - | - | - | - | - | - | - | $1.62M | $566.00K | $343.00K | $824.00K | $3.78M | $722.00K | - | - | - | - |
| Collaborative | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Service | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $250.00K | $250.00K | $250.00K | $250.00K |
| Provision of Data | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.20M | $3.80M | - |
| Provision of Data and Fulfillment of Milestones | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.20M | - | - |
Veracyte's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Testing (93.25%), Product (3.65%), and Biopharmaceutical And Other (3.10%).
Veracyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Non-US | $33.61M | $18.53M | $7.87M |
| UNITED STATES | $262.92M | $200.98M | $109.61M |
Veracyte's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (88.66%), and Non-US (11.34%).
Quarterly Revenue by Country
| Country | Dec 23 |
|---|---|
| Non-US | $26.53M |
| UNITED STATES | $334.52M |
Veracyte's latest quarterly revenue breakdown by geography, as of Dec 23: UNITED STATES (92.65%), and Non-US (7.35%).
Veracyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VCYT | Veracyte | $361.05M | $96.84M |
| ENTA | Enanta Pharmaceuticals | $79.20M | $17.97M |
| RYTM | Rhythm Pharmaceuticals | $77.43M | $25.97M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| QURE | uniQure | $15.84M | $11.13M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| FIXX | Q32 Bio | $1.16M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| GPCR | Structure Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| VTYX | Ventyx Biosciences | - | - |
| SLDB | Solid Biosciences | - | - |
VCYT Revenue FAQ
What is Veracyte’s yearly revenue?
Veracyte's yearly revenue for 2023 was $361.05M, representing an increase of 21.76% compared to 2022. The company's yearly revenue for 2022 was $296.54M, representing an increase of 35.09% compared to 2021. VCYT's yearly revenue for 2021 was $219.51M, representing an increase of 86.85% compared to 2020.
What is Veracyte’s quarterly revenue?
Veracyte's quarterly revenue for Q4 2023 was $96.84M, a -1.38% decrease from the previous quarter (Q3 2023), and a 17.50% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $98.2M, a 8.98% increase from the previous quarter (Q2 2023), and a 22.29% increase year-over-year (Q3 2022). VCYT's quarterly revenue for Q2 2023 was $90.11M, a -0.24% decrease from the previous quarter (Q1 2023), and a 19.20% increase year-over-year (Q2 2022).
What is Veracyte’s revenue growth rate?
Veracyte's revenue growth rate for the last 3 years (2021-2023) was 64.48%, and for the last 5 years (2019-2023) was 199.96%.
What are Veracyte’s revenue streams?
Veracyte's revenue streams in c 22 are Biopharmaceutical And Other, Testing, and Product. Biopharmaceutical And Other generated $33.36M in revenue, accounting 11.25% of the company's total revenue, up 67.91% year-over-year. Testing generated $250.54M in revenue, accounting 84.49% of the company's total revenue, up 325.66% year-over-year. Product generated $12.63M in revenue, accounting 4.26% of the company's total revenue, up 28.31% year-over-year.
What is Veracyte’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Veracyte was Testing. This segment made a revenue of $250.54M, representing 84.49% of the company's total revenue.